Physician profile
Michelle Levin
NPI 1225318975
$8,341.66
in general payments reported to CMS, 2019-2025
32 companies · $973 in 2025
The $973 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,146 · 2020: $575 · 2021: $1,201 · 2022: $1,478 · 2023: $1,342 · 2024: $626 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,940.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,221.97 | 2019-2023 | Myday Contact Lens, Misight Contact Lens |
| Mallinckrodt Hospital Products INC. | $989.49 | 2021-2025 | Acthar |
| Allergan, INC. | $952.29 | 2019-2021 | |
| Abbvie INC. | $691.64 | 2022-2025 | |
| Johnson & Johnson Vision Care, INC. | $478.86 | 2021-2025 | |
| Optovue, INC. | $376.43 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $372.26 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sight Sciences, INC. | $352.96 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $347.14 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $324.47 | 2019-2025 | Cequa |
| Shire North American Group INC | $293.24 | 2019 | |
| Oyster Point Pharma, INC. | $284.61 | 2022-2024 | Tyrvaya |
| Biotissue Holdings INC. | $256.10 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $158.17 | 2023 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $145.83 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $136.05 | 2019-2021 | |
| New World Medical,INC. | $119.29 | 2023 | |
| Maculogix, INC. | $113.03 | 2019 | |
| Visionix USA, INC | $99.74 | 2022 | |
| Dompe US, INC. | $91.13 | 2021-2025 | Oxervate |
| Lkc Technologies, INC. | $89.53 | 2025 | |
| Topcon Healthcare, INC. | $75.46 | 2021 | |
| Lombart Brothers, INC. | $68.69 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $57.05 | 2024-2025 | Xdemvy |
| Lumibird Medical INC. | $53.88 | 2019 | |
| Alcon Vision LLC | $46.84 | 2023-2025 | Eysuvis, Clareon |
| Astellas Pharma US INC | $37.89 | 2024 | Izervay |
| Harrow Eye, LLC | $26.68 | 2025 | Vevye |
| Thea Pharma INC. | $25.66 | 2023 | Iyuzeh |
| Amgen INC. | $21.18 | 2024 | Tepezza |
| Horizon Therapeutics Plc | $17.85 | 2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $16.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.